INTRODUCTION
Multiple myeloma (MM) is a relatively uncommon malignancy of plasma cell origin that often appears to have multicentric origin within bone. This disease makes up about 1% of all malignancies and 10% to 15% of hematologic malignancies. [1] It is difficult to estimate the prevalence of oral manifestations as the initial feature of this disease because most cases are presented as case reports or in retrospective studies. Its presence in jaws is not a rare condition, but oral lesions rarely occur as the first sign of the disease and when present, angle and ramus of the mandible is the most common site. [2, 3] This report presents a 40-year-old male patient diagnosed with MM from the primary manifestation of an intraoral lesion.
CLINICAL PRESENTATION
A 40-year-old male patient reported with the complaint of an unhealed socket for 2 months. The patient gave the history of mild lower facial swelling on the left side for 3-4 months, which was diagnosed as a case of cellulitis, and treated by extraction of the third molar on the same side 2 months back by a local dental practitioner. He also gave the history of troublesome bleeding during extraction, which was managed by local measures and complained the numbness present on lower lip following the extraction. He also complained of fatigue, malaise and mild backache.
with no surface changes [ Figure 1 ]. Intraoral examination revealed an unhealed extraction socket in mandibular left retromolar area, associated with mild buccal cortical expansion and vestibular obliteration, extending till 36.
The panoramic radiograph revealed a multilocular radiolucency extending from the mandibular ramus area till mesial aspect of 36. The lesion had caused the resorption of roots of 36 and 37 [ Figure 2 ]. The three-dimensional computed tomography (CT) image also showed a large osteolytic lesion demonstrating the complete erosion of both buccal and lingual cortex [ Figure 3a and b].
All the hematological tests were performed and found to be within the normal limits except for mild anemia and raised erythrocyte sedimentation rate. An incisional biopsy yielded a red beefy colored tissue. Excessive bleeding was noted during biopsy and was controlled by pressure packs. Histopathological examination of the H and E sections [ Figure 4a and b] revealed round to ovoid cells with hyperchromatic eccentrically located nuclei and granular chromatin arranged in a "cartwheel" fashion, arranged in the form of sheets of monoclonal appearing cells plasmacytes.
Perinuclear halo was evident in few cells. Few cells were shown to possess eosinophilic crystalline inclusions such as Russell bodies, Dutcher bodies, Mott bodies [ Figure 4c and d]. Atypical plasma cells with many binucleate, trinucleate and multinucleate forms were also noted [ Figure 4e ]. The histopathological diagnosis made was plasmacytoma, and the patient was reinvestigated for MM.
Lateral skull radiograph revealed a solitary punched out lesion of the parietal bone [ Figure 5 ]. Skeletal radiographic 
DISCUSSION
Plasma cell myeloma (plasmacytoma) is a B-cell lymphoid neoplasm and may present as one of three distinct clinical entities: MM, solitary plasmacytoma of bone and extramedullary plasmacytoma. [4] The relationship between localized form and MM is not completely understood, but 36%-85% of solitary plasmacytoma may develop into MM. [5] Samual Solley in 1844 first described a well-documented case of MM, and the term "MM" was coined by J. von Rustizky in 1873. [6] MM is also known as Kahler's disease (after Otto Kahler). [7] MM is the most common primary malignancy of bone. [8] MM is more common in males, with a male: female ratio of 3:2. MM is seen more often in patients between 50 and 80 years of age, with a mean age of 60 years. The incidence rises with age. [9] Although the etiology remains uncertain, certain etiologic agents such as radiation, exposure to chemicals, viruses and genetic factors have been implicated. Plasmacytoma has been reported in HIV-positive patients. Moreover, HCV seroprevalence has been also identified in bone marrow of patients affected by MM, indicating the role of HCV infection as risk factor for the development of several hematological malignancies. Some studies suggest that oncogenes such as C-Myc, Ras and possibly tumor suppressor genes such as Rb, p53 or p16, may be involved in the pathogenesis of this disease. Moreover, viral and serological studies have demonstrated that there is a consistent association between the human herpesvirus type 8 and Kaposi's sarcoma, primary lymphoma and Castleman's disease (angiofollicular lymphoid hyperplasia). [4, 10] MM has a predilection for areas of active hematopoiesis such as the lumbar spine, ribs and pelvic bones. [11] Jawbone involvement often occurs in the advanced stages of the disease. Jaw involvement in MM was reported by Bruce and Royer to have a prevalence rate of 28.8% (17 of 59 total cases). [12] In a review, Epstein et al. found that 14.1% of 783 reported MM cases had oral manifestations and Lambertenghi-Deliliers et al. determined that jawbone involvement occurred with a prevalence rate of 5.18%. [13, 14] Maxillofacial manifestations as an initial sign or symptom of MM are rare and are mostly reported as case studies. Swelling has been described as the most common sign, with pain, expansion of the jaw, numbness, mobility of the teeth, epulis formation, macroglossia due to amyloid deposition and pathologic fracture of the jawbone also being reported. [10, 11] Lesions are more frequently found in the mandible than in the maxilla, especially in the posterior region and angle of the jaw, perhaps because of greater hematopoietic activity in these areas. [15] Cases have been reported in condyle and parasymphyseal area, tuberosity, pterygoid apophysis, palate and zygoma. [10] Apart from the oral cavity, MM has been reported in various head and neck regions such as paranasal sinuses, parotid gland, cranial base, cerebral and frontal regions with varying degrees of neurological deficits. [16] [17] [18] [19] [20] On radiographic evaluation, jawbone lesions appear mostly as "punched-out" osteolytic lesions, although generalized osteoporosis may also be seen. [11] The most frequent radiographic characteristics in MM are osteolytic lesions with a "soap bubble" appearance, [10, 21] as was observed in the present case.
The diagnosis of MM may be established by laboratorial examinations, such as hematologic, biochemical findings, urine analysis and skeletal radiographic survey. The calcium, renal, anemia and bone lesions (CRAB) criteria were examined, and only anemia and bone lesions were observed. Anemia is probably related to hemolysis due to the excess of paraproteins, although no myeloma proteins in the urine were observed in the current case. [22] The diagnostic criteria for MM include evidence of multiple osteolytic lesions, identification of an atypical plasma cell population on biopsy and abnormalities of immunoglobulin production. [23] Hence, based on the histopathology, immunohistochemical reaction and osteolytic lesions on the radiographic survey, the diagnosis of MM was given.
Morphological features of the neoplastic plasma cells are highly variable, ranging from plasmablasts with a prominent solitary nucleolus to mature looking plasma cell. Several classifications have been reported, demonstrating the morphology of plasma cell as a useful prognostic factor, independent of or in addition to other biologic values. Unusual aberrations of the nuclei and cytoplasm were reported in these instances including cleaved nuclei, multilobated nuclei and/or giant cells, tadpole-like cells, monocytoid nuclei, nuclear pseudoinclusions (Dutcher bodies), cytoplasmic Ig inclusions (Russel bodies), spherical inclusions packed in their cytoplasm (Mott bodies) clear cytoplasm, signet ring cells, flaming cytoplasm, cytoplasmic vacuolation, erythro-or iron-containing plasma cell, phagocytosis and cytoplasmic crystals. Whereas prognosis was clearly related to nuclear changes, no prognostic value has been related to cytoplasmic anomalies mainly because each of the latter are too occasional. [24] Bone pain, especially back pain is a major symptom reported by patients, attributed to osteoclast activating factor, a lymphokine, responsible for bone changes. [8] Bone lesions are induced by neoplastic cells in bone marrow (i.e., neoplastic plasma cells) which release osteoclast activating factor, so inducing osteoclasts activation. Glucocorticoids administration may be helpful in the management of bone pain. [22] The patient described in the present case also had mild lower back pain which may be explained by bone resorption activity, although radiographic survey revealed no osteolytic lesions except in the jaw and skull bone.
An increase in vascular endothelial growth factor, transforming growth factor beta 1 and interleukin 6 (IL-6) levels have been found in patients with lymphoproliferative disorders. IL-6 is considered as the principal growth factor in the pathogenesis of MM. Furthermore, an increased level of endostatin has also been found in active phases of MM. Furthermore, osteopontin, produced by both osteoclasts and osteoblasts seem to play an important role in accelerated bone loss in myeloma. [22] There are a number of concerns for the general dental practitioner with regards to treating a patient with MM. Bleeding tendencies occur as a result of thrombocytopenia and from high levels of the abnormal circulating proteins, which interfere with coagulation. [9, 10] The cause of excessive hemorrhage during biopsy in the present case is not known as the hematological investigations revealed no abnormal findings. Although it may be related to neovascularization of the lesion. [25] Renal failure may also occur as a result of excessive serum proteins. Susceptibility to infection increases as immune paresis occurs, and the level of circulating, normal immunoglobulins, decreases. If a patient is to undergo dental treatment it is vital to determine their current renal status and medication. Chemotherapy and steroid therapy affect the patient's bone marrow and adrenal function, respectively. Elective dental treatment should be avoided and ideally be performed when the patient is in remission. [9] MM is not curable; however, the prognosis of the patient depends on the stage of the disease at the time of diagnosis. In the recent years, high-dose chemotherapy with hematopoietic stem cell transplantation has become the preferred treatment for patients under the age of 65 years. [26] Systemic chemotherapy usually controls oral lesions. Palliative radiotherapy for lytic jawbone lesions can also be used. The combination of thalidomide and dexamethasone, often in combination with melphalan, is one of the most common regimens for patients with newly diagnosed MM. Bisphosphonates reduce the risk of myeloma-related fracture, but bisphosphonate-related osteonecrosis of the jaws occurs in a small percentage of the patients. [25] The prognosis of MM is poor, with a survival rate of approximately 3-10 years from the time of diagnosis. [8] The combination of thalidomide and bisphosphonate was used in our case, and the patient showed reduction in the swelling and healed extraction socket after 3 months .
CONCLUSION
Oral lesions are seen with some frequency in patients with MM, and this may be the initial sign of systemic disease. Dental surgeons can play a significant role in the early recognition of oral lesions with underlying systemic disease, thus preventing the morbidity and mortality associated with such pathologies. In addition, oral surgeons are expected to have a sound knowledge of this condition not only in the early detection, but also in the treatment of patients with MM, thus improving the quality of life of the affected individuals.
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